Zynex specializes in non-invasive pain management and patient monitoring, with promising advancements. Read why I think ZYXI ...

Zynex is cutting 15% of its workforce after health insurance company Tricare temporarily suspended payments. The medical device maker said Tuesday it plans to cut jobs because Tricare has suspended ...

Shares of Zynex fell after the it said that the health insurance company Tricare--which accounts for as much as 25% of its total revenue--has temporarily suspended payments as it reviews prior claims.

Good afternoon, ladies and gentlemen, and welcome to the Zynex fourth-quarter 2024 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like ...

Q4 2024 Earnings Call Transcript March 11, 2025 Operator: Good afternoon, ladies and gentlemen, and welcome to the Zynex ...

RBC Capital downgraded Zynex (ZYXI) to Sector Perform from Outperform with a price target of $5.50, down from $11. The firm says the company’s ...

Zynex develops, manufactures, markets and sells medical devices used for nerve stimulation, pain management, and rehabilitation, as well as non-invasive fluid, sepsis, and laser-based pulse oximetry ...

Despite a net loss and TRICARE payment suspension, Zynex Inc (ZYXI) shows resilience with revenue growth and strategic ...

Law Offices of Howard G. Smith announces an investigation on behalf of Zynex, Inc. ("Zynex" or the "Company") investors concerning the Company's possible violations of federal securities laws. IF YOU ...

The Law Offices of Frank R. Cruz announces an investigation of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) on behalf of investors concerning ...

Zynex cited slower payments from certain payers and a temporary payment suspension by Tricare, which represents 20-25% of annual revenue, as reasons for the revenue shortfall. In response, the company ...